These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 7474246

  • 21. Cytochrome P-450IID6 phenotyping in cancer patients: debrisoquin and dextromethorphan as probes.
    Anthony LB, Boeve TJ, Hande KR.
    Cancer Chemother Pharmacol; 1995; 36(2):125-8. PubMed ID: 7767948
    [Abstract] [Full Text] [Related]

  • 22. Metabolism of ophthalmic timolol: new aspects of an old drug.
    Volotinen M, Hakkola J, Pelkonen O, Vapaatalo H, Mäenpää J.
    Basic Clin Pharmacol Toxicol; 2011 May; 108(5):297-303. PubMed ID: 21385322
    [Abstract] [Full Text] [Related]

  • 23. Cardiac safety of ophthalmic timolol.
    Mäenpää J, Pelkonen O.
    Expert Opin Drug Saf; 2016 Nov; 15(11):1549-1561. PubMed ID: 27534869
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.
    Schadel M, Wu D, Otton SV, Kalow W, Sellers EM.
    J Clin Psychopharmacol; 1995 Aug; 15(4):263-9. PubMed ID: 7593709
    [Abstract] [Full Text] [Related]

  • 26. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
    Speirs CJ, Murray S, Boobis AR, Seddon CE, Davies DS.
    Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Dynamics and kinetics of ophthalmic timolol.
    Affrime MB, Lowenthal DT, Tobert JA, Shirk J, Eidelson B, Cook T, Onesti G.
    Clin Pharmacol Ther; 1980 Apr; 27(4):471-7. PubMed ID: 7357805
    [Abstract] [Full Text] [Related]

  • 29. Cardiovascular effects of ophthalmic timolol.
    Leier CV, Baker ND, Weber PA.
    Ann Intern Med; 1986 Feb; 104(2):197-9. PubMed ID: 3946944
    [Abstract] [Full Text] [Related]

  • 30. Excessive beta-blockade with timolol eye drops.
    Kalenak JW.
    JAMA; 1996 Apr 03; 275(13):985; author reply 986. PubMed ID: 8596251
    [No Abstract] [Full Text] [Related]

  • 31. Excessive beta-blockade with timolol eye drops.
    Novack GD.
    JAMA; 1996 Apr 03; 275(13):985; author reply 986. PubMed ID: 8596252
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Comparison of the cardiovascular effects of unoprostone 0.15%, timolol 0.5% and placebo in healthy adults during exercise using a treadmill test.
    Stewart WC, Stewart JA, Crockett S, Kubilus C, Brown A, Shams N.
    Acta Ophthalmol Scand; 2002 Jun 03; 80(3):272-6. PubMed ID: 12059865
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. The lack of efficacy of topical beta-blockers, timolol and betaxolol on intraocular pressure in Nigerian healthy volunteers.
    Olateju SO, Ajayi AA.
    Eye (Lond); 1999 Dec 03; 13 ( Pt 6)():758-63. PubMed ID: 10707140
    [Abstract] [Full Text] [Related]

  • 39. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
    Heiskanen T, Olkkola KT, Kalso E.
    Clin Pharmacol Ther; 1998 Dec 03; 64(6):603-11. PubMed ID: 9871425
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.